Skip to content
Screener

Pacific Biosciences of California PACB Service — Contract with customer, liability

Similar metrics at other companies

Las Vegas Sands logo
LVSMall — Contract with customer, liability
$172M-1.7%
QT Imaging Holdings, Inc. logo
QTIDistribution — Contract with customer, liability
$51M
Zevra Therapeutics, Inc. logo
ZVRALicense — Contract with customer, liability
$0
Honeywell International logo
HONLicense — Contract with customer, liability
$18.75M
BridgeBio Pharma logo
BBIOResearch and Development Services — Contract with customer, liability
$2.5M
Choice Hotels International logo
CHHLoyalty program — Contract with customer, liability
$114.9M+4.1%

Other financials

Income statement

See full
Revenue$39.0M-1.9%
Gross profit$12.6M-13.9%
Operating income-$44.6M+0.5%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation

See full
Market cap$357.46M-5.6%
Enterprise value$356.64M-4.8%
P/S2.2×-0.2×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio4.9×-2.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001299130-26-000122

As of June 30, 2026, we had a total of $19.4 million of deferred revenue, $16.1 million of which was recorded as deferred revenue, current, and $3.3 million of which was recorded as deferred revenue, non-current, which primarily relates to deferred service contract revenues and is scheduled to be recognized in the next six years. Revenue recorded in the three and six months ended June 30, 2026 includes $3.7 million and $8.7 million, respectively, that was included in deferred revenue as of December 31, 2025.

Item 1. Financial Statements (unaudited):

FAQ

What is Pacific Biosciences of California's service — contract with customer, liability?
Pacific Biosciences of California (PACB) reported service — contract with customer, liability of $19.4M in Q2 2026.
How has Pacific Biosciences of California's service — contract with customer, liability changed year-over-year?
Pacific Biosciences of California's service — contract with customer, liability decreased by 5.8% year-over-year, from $20.6M to $19.4M.
What is the long-term trend for Pacific Biosciences of California's service — contract with customer, liability?
Over 2 years (2021 to 2025), Pacific Biosciences of California's service — contract with customer, liability has grown at a -9.1% compound annual growth rate (CAGR), from $99.2M to $82M.
What does service — contract with customer, liability mean?
This represents the total financial obligation arising from service agreements where the company has received consideration but has not yet satisfied the performance obligations. It reflects the balance of unearned service revenue that must be fulfilled through future maintenance, support, or technical assistance. Monitoring this liability helps assess the company's future service delivery commitments and potential for future revenue recognition.

Ask your AI about Pacific Biosciences of California's service — contract with customer, liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude